iOnctura Names New CFO and COO to Strengthen Leadership

iOnctura, a clinical-stage biopharmaceutical company focused on tackling neglected and challenging cancers, has made key additions to its leadership team by appointing Steven Sciuto as Chief Financial Officer (CFO) and Michelle Tsai as Chief Operating Officer (COO). These appointments are aligned with the company's strategic moves for further development and market penetration, following the initiation of Phase II studies for their lead asset, roginolisib. Steven Sciuto brings extensive experience in scaling finance operations and fundraising across the life sciences sector, highlighting a strong track record in securing over $400 million in financings. He previously worked at Neurogene Inc. Michelle Tsai joins with a robust background in oncology and pharmaceutical commercialization, having led successful global launches for Novartis. Her expertise in strategy and lifecycle planning is expected to play a pivotal role in advancing iOnctura's pipeline. iOnctura's main drug, roginolisib, is being developed as a promising PI3K inhibitor for treating cancers with historically difficult treatment profiles due to its unique allosteric modulation mechanism. The company is supported by institutional investors including Syncona, M Ventures, Inkef Capital, and others. Based in Geneva and Amsterdam, iOnctura is positioning itself for transformative growth and aims to create life-changing therapies.